Ginés Luengo-Gil

Dr. Ginés Luengo-Gil

Grupo de Investigación en Patología Molecular y Farmacogenética, Servicio de Anatomía Patológica, Hospital General Universitario Santa Lucía, IMIB-Arrixaca, Cartagena, Spain.
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2014 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MMMaría Martínez-García
María Martínez-García
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
ABAsunción Chaves Benito
Asunción Chaves Benito
EGEnrique González-Billalabeitia
Enrique González-Billalabeitia
MCMaría Angeles Vicente Conesa
María Angeles Vicente Conesa
FPFrancisco Ayala de la Peña
Francisco Ayala de la Peña
Introduction: Tumor microenvironment immunity is associated with breast cancer outcome. A high lymphocytic infiltration has been associated with response to neoadjuvant chemotherapy, but the contribution to response and prognosis of immune cell subpopulations profiles in both pre-treated and post-treatment residual tumor is still unclear. Methods: We analyzed pre- and post-treatment tumor-infiltrating immune cells (CD3, CD4, CD8, CD20, CD68, Foxp3) by immunohistochemistry in a series of 121 breast cancer patients homogeneously treated with neoadjuvant chemotherapy. Immune cell profiles were analyzed and correlated with response and survival. Results: We identified three tumor-infiltrating immune cell profiles, which were able to predict pathological complete response (pCR) to neoadjuvant chemotherapy (cluster B: 58%, versus clusters A and C: 7%). A higher infiltration by CD4 lymphocytes was the main factor explaining the occurrence of pCR, and this association was validated in six public genomic datasets. A higher chemotherapy effect on lymphocytic infiltration, including an inversion of CD4/CD8 ratio, was associated with pCR and with better prognosis. Analysis of the immune infiltrate in post-chemotherapy residual tumor identified a profile (cluster Y), mainly characterized by high CD3 and CD68 infiltration, with a worse disease free survival. Conclusions: Breast cancer immune cell subpopulation profiles, determined by immunohistochemistry-based computerized analysis, identify groups of patients characterized by high response (in the pre-treatment setting) and poor prognosis (in the post-treatment setting). Further understanding of the mechanisms underlying the distribution of immune cells and their changes after chemotherapy may contribute to the development of new immune-targeted therapies for breast cancer.

3 December 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JGJaime Guillén
Jaime Guillén
CFCristina Ferrer-Orta
Cristina Ferrer-Orta
MBMònica Buxaderas
Mònica Buxaderas
DPDolores Pérez-Sánchez
Dolores Pérez-Sánchez
MGMARTA GUERRERO-VALERO
MARTA GUERRERO-VALERO
SCSenena Corbalán-García
Senena Corbalán-García
Significance: Vesicle fusion is an important event in neuronal transmission and endocrine cell secretion. A myriad of proteins containing double C2 domains are involved in this complex process; however, how Ca 2+ and the different types of membrane lipids regulate their function is still not well understood. In this work, we provide structural insights to explain the ability of different C2 domains to interact with Ca 2+ and PI(4,5)P 2 and demonstrate the existence of a specific PI(4,5)P 2 -binding motif that provides these domains with specific properties to interact with the membrane and initiate vesicle fusion. We also demonstrate a unique molecular mechanism conferring their specificity for the different phosphoinositides, which resides in additional amino acidic residues surrounding the key interacting lysines.

4 April 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
EGEnrique Gonzalez-Billalabeitia
Enrique Gonzalez-Billalabeitia
SPSergio Alejo Perez-Henarejos
Sergio Alejo Perez-Henarejos
EMEsther Navarro Manzano
Esther Navarro Manzano
ACAsuncion Chaves-Benito
Asuncion Chaves-Benito
FPFrancisco Ayala de la Peña
Francisco Ayala de la Peña
Angiogenesis is a key process for tumor progression and a target for treatment. However, the regulation of breast cancer angiogenesis and its relevance for clinical resistance to antiangiogenic drugs is still incompletely understood. Recent developments on the contribution of microRNA to tumor angiogenesis and on the oncogenic effects of miR-17-92, a miRNA cluster, point to their potential role on breast cancer angiogenesis. The aim of this work was to establish the contribution of miR-20a, a member of miR-17-92 cluster, to tumor angiogenesis in patients with invasive breast carcinoma. Tube-formation in vitro assays with conditioned medium from MCF7 and MDA-MB-231 breast cancer cell lines were performed after transfection with miR-20a and anti-miR20a. For clinical validation of the experimental findings, we performed a retrospective analysis of a series of consecutive breast cancer patients (n = 108) treated with neoadjuvant chemotherapy and with a full characterization of their vessel pattern and expression of angiogenic markers in pre-treatment biopsies. Expression of members of the cluster miR-17-92 and of angiogenic markers was determined by RT-qPCR after RNA purification from FFPE samples. In vitro angiogenesis assays with endothelial cells and conditioned media from breast cancer cell lines showed that transfection with anti-miR20a in MDA-MB-231 significantly decreased mean mesh size and total mesh area, while transfection with miR-20a in MCF7 cells increased mean mesh size. MiR-20a angiogenic effects were abrogated by treatment with aflibercept, a VEGF trap. These results were supported by clinical data showing that mir-20a expression was higher in tumors with no estrogen receptor or with more extensive nodal involvement (cN2-3). A higher miR-20a expression was associated with higher mean vessel size (p = 0.015) and with an angiogenic pattern consisting in larger vessels, higher VEGFA expression and presence of glomeruloid microvascular proliferations (p<0.001). This association was independent of tumor subtype and VEGFA expression. Transfection of breast cancer cells with miR-20a induces vascular changes in endothelial tube-formation assays. Expression of miR-20a in breast invasive carcinomas is associated with a distinctive angiogenic pattern consisting in large vessels, anomalous glomeruloid microvascular proliferations and high VEGFA expression. Our results suggest a role for miR-20a in the regulation of breast cancer angiogenesis, and raise the possibility of its use as an angiogenic biomarker.

1 April 2013 in The Oncologist
Verified
Journal Article
Closed access
PDF file
ACAlmudena Cascales
Almudena Cascales
FPFrancisco Pastor-Quirante
Francisco Pastor-Quirante
BSBeatriz Sánchez-Vega
Beatriz Sánchez-Vega
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
JCJavier Corral
Javier Corral
FPFrancisco Ayala de la Peña
Francisco Ayala de la Peña
Objective.: Treatment with anthracyclines may cause cardiac dysfunction, but the sequence of anthracycline-induced heart lesions has been incompletely characterized. NADPH oxidase, a key mediator of oxidative cardiac damage and remodeling, modulates anthracycline clinical cardiotoxicity. Our aim was to determine which cardiac histological lesions are specifically induced by anthracycline treatment and to investigate the role of NADPH functional genetic polymorphisms in their development. Patients and Methods.: Using a retrospective case–control design, we evaluated cardiac histological lesions and NADPH genotype (polymorphisms rs1883112, rs4673, and rs13058338) in 97 consecutive decedents with a cancer diagnosis (48 treated with anthracyclines). Results.: Myocytolysis (60%), patched myocardial necrosis (19%), and myocardial fibrosis (diffuse and patched; 62% and 23%, respectively) were associated with anthracycline treatment. In patients receiving anthracyclines, NADPH oxidase polymorphism rs4673 protected against focal myocardial necrosis (odds ratio [OR], 0.11; 95% confidence interval [CI], 0.20–0.63) whereas rs1883112 was strongly associated with cardiac fibrosis (OR, 5.11; 95% CI, 1.59–16.43), which was present in all homozygotes. Conclusion.: Anthracyclines induce a cardiac remodeling pattern characterized by interstitial or patched fibrosis. The contribution of the functionally relevant NADPH polymorphisms rs1883112 and rs4673 to anthracycline-related heart lesions provides a plausible explanation for their modulation of cardiotoxicity. If confirmed, these findings may lead to better individualized strategies for early detection and prevention of anthracycline cardiotoxicity.

12 June 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
AMAhsen Morva
Ahsen Morva
AAAna B. Arroyo
Ana B. Arroyo
LALiudmila Andreeva
Liudmila Andreeva
ATAna Tapia-Abellán
Ana Tapia-Abellán
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
Chimeric antigen receptor (CAR) macrophage therapy represents a promising new frontier in cancer immunotherapy, with the potential to overcome the limitations of CAR-T cell approaches, particularly in solid tumours. This comprehensive review focuses on the current state and future prospects of CAR macrophage technology, emphasising its applications in solid malignancies across preclinical and early clinical development. The key topics covered included CAR design optimisation, macrophage sources and engineering strategies, mechanisms of antitumour activity, in vivo efficacy in animal models, initial clinical trial results, and challenges for broader implementation. The unique properties of macrophages, including tumour penetration and microenvironment modulation, offer significant advantages over T cell-based therapies in solid-tumour settings. However, strategies to enhance persistence, maintain proinflammatory phenotypes, and improve manufacturing are required. Although early research suggests additional applications beyond oncology, including for infectious and inflammatory diseases, this review primarily concentrates on the oncologic potential of CAR-M therapies. Continued optimisation and larger randomised trials will be critical to establish clinical efficacy and define the role of this approach in the treatment of solid tumours.

Verified
Journal Article
Open access
PDF file
JPJulia Peñas-Martínez
Julia Peñas-Martínez
MBMaria Barrachina
Maria Barrachina
EZErnesto Cuenca Zamora
Ernesto Cuenca Zamora
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
SLSusana Belen Bravo López
Susana Belen Bravo López
FFFrancisca Ferrer
Francisca Ferrer
Exosomes are extracellular vesicles that contain nucleic acids, lipids and metabolites, and play a critical role in health and disease as mediators of intercellular communication. The majority of extracellular vesicles in the blood are platelet-derived. Compared to adults, neonatal platelets are hyporeactive and show impaired granule release, associated with defects in Soluble N-ethylmaleimide-sensitive fusion Attachment protein REceptor (SNARE) proteins. Since these proteins participate in biogenesis of exosomes, we investigated the potential differences between newborn and adult plasma-derived exosomes. Plasma-derived exosomes were isolated by ultracentrifugation of umbilical cord blood from full-term neonates or peripheral blood from adults. Exosome characterization included size determination by transmission electron microscopy and quantitative proteomic analysis. Plasma-derived exosomes from neonates were significantly smaller and contained 65% less protein than those from adults. Remarkably, 131 proteins were found to be differentially expressed, 83 overexpressed and 48 underexpressed in neonatal (vs. adult) exosomes. Whereas the upregulated proteins in plasma exosomes from neonates are associated with platelet activation, coagulation and granule secretion, most of the underexpressed proteins are immunoglobulins. This is the first study showing that exosome size and content change with age. Our findings may contribute to elucidating the potential “developmental hemostatic mismatch risk” associated with transfusions containing plasma exosomes from adults.